STOCK TITAN

AstraZeneca wins FDA approval for Klygefa

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

AstraZeneca PLC (AZN) announced that the US FDA approved Klygefa (gefurulimab) on November 16, 2026, for adults with generalised myasthenia gravis (gMG) who are anti-AChR antibody positive. The medicine is administered once weekly by subcutaneous autoinjector.

In the Phase III PREVAIL trial, the week 26 treatment difference in MG-ADL total score versus placebo was -1.6 (95% CI: -2.4 to -0.8; p<0.0001); clinical improvement was observed as early as week one. Klygefa was generally well-tolerated, and most treatment-emergent adverse events were mild to moderate. The most common reported events were injection site reactions (12%), back pain (8%) and vomiting (5%).

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointFDA approval on November 16, 2026 covers adult AChR-positive gMG.

Negative

  • None.
Week 26 MG-ADL treatment difference -1.6 (95% CI: -2.4 to -0.8) Klygefa versus placebo in PREVAIL
p-value <0.0001 Week 26 PREVAIL primary endpoint
PREVAIL participants 260 patients Trial enrolled patients from 20 countries
People diagnosed with gMG in the US 98,500 people AstraZeneca estimate
US gMG patients who are AChR-positive 81,000 people AstraZeneca estimate
Injection site reactions 12% Most common treatment-emergent adverse events among Klygefa recipients
Back pain 8% Treatment-emergent adverse events among Klygefa recipients
Vomiting 5% Treatment-emergent adverse events among Klygefa recipients
generalised myasthenia gravis (gMG) medical
"treatment of generalised myasthenia gravis (gMG) in adult patients"
dual-binding nanobody technical
"first and only dual-binding nanobody C5 inhibitor"
MG-ADL total score medical
"change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score"
treatment emergent adverse events (TEAEs) medical
"percentage of participants with treatment emergent adverse events (TEAEs)"
Treatment-emergent adverse events (TEAEs) are any new side effects or worsening of existing health problems that begin after a person starts a drug or medical treatment during a clinical trial or real-world use. Investors watch TEAEs because they reveal a product’s safety profile and can affect regulatory approval, prescribing restrictions, market acceptance and legal risk—like warning lights that signal potential problems with a new car.
terminal complement cascade medical
"C5 protein in the terminal complement cascade"
open-label extension medical
"continue into an open-label extension period"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the FDA approve AZN's Klygefa to treat?

The FDA approved Klygefa (gefurulimab) for adults with generalised myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive. AstraZeneca says it is administered once weekly by subcutaneous self-injection using an autoinjector.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of November 2026 
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 

AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Klygefa (gefurulimab) approved in the US
 
 
  
16 November 2026
 
Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients
 
Approval supported by PREVAIL Phase III results showing statistically significant and clinically meaningful improvements in activities of daily living starting as early as week one and sustained through one year
 
First and only approved dual-binding nanobody C5 inhibitor in the US, offering once-weekly subcutaneous self-administration via autoinjector with rapid and sustained disease control
 
Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.
 
The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal PREVAIL Phase III trial. Results from the trial showed that Klygefa met its primary endpoint, demonstrating improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001). In addition to the week 26 prespecified results, clinical improvement was observed as early as week one.1
 
gMG is a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness.2 In the US, an estimated 98,500 people are diagnosed with gMG with 81,000 being AChR-positive.3
 
Kelly Gwathmey, MD, associate professor in the Department of Neurology’s Division of Neuromuscular Medicine at Columbia University Vagelos College of Physicians and Surgeons; member of the MGFA Medical & Scientific Advisory Council; and principal investigator in the trial at Virginia Commonwealth University, said: “gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals. In the PREVAIL Phase III trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection. With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition.”
 
Samantha Masterson, President & Chief Executive Officer, Myasthenia Gravis Foundation of America (MGFA), said: “For the gMG community, every new approved treatment represents more than a clinical advance; it also represents choice. Because no two patients experience gMG in the same way, expanding the range of options available is fundamental to how we improve lives. The MGFA welcomes this approval and the new possibilities it opens for those who have been seeking more independence and greater control of their treatment administration.”
 
Marc Dunoyer, Chief Executive Officer, Alexion, said: “The US approval of Klygefa delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 inhibition with the flexibility of once-weekly subcutaneous self-administration via autoinjector. We are proud to have discovered and developed this novel dual-binding nanobody, and look forward to soon delivering this pioneering innovation to adults with gMG in the US, offering the established efficacy and safety of C5 inhibition with added convenience.”
 
Klygefa was generally well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG. The percentage of participants with treatment emergent adverse events (TEAEs) was similar between those who received Klygefa and placebo, and most TEAEs observed were mild to moderate in severity (grade 1 or 2). The most common TEAEs seen in those receiving Klygefa were injection site reactions (12%), back pain (8%) and vomiting (5%).1
 
The data from the PREVAIL trial were presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.1
 
Klygefa is approved in the European Union (EU), Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.
 
Notes
 
Generalised Myasthenia Gravis (gMG)
Generalised myasthenia gravis (gMG) is a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness.2
 
Eighty-five percent of people with gMG are AChR antibody-positive meaning they produce specific antibodies (anti-AChR) that bind to signal receptors at the neuromuscular junction (NMJ), the connection point between nerve cells and the muscles they control.4 This binding activates the complement system, causing the immune system to attack the NMJ, leading to inflammation and a breakdown in communication between the brain and the muscles.5
 
gMG can occur at any age, but it most commonly begins for women before the age of 40 and for men after the age of 60.6 Initial symptoms may include slurred speech, double vision, droopy eyelids and lack of balance; these can often lead to more severe symptoms as the disease progresses, such as impaired swallowing, choking, extreme fatigue and respiratory failure.7,8
 
PREVAIL (ALXN1720-MG-301)
PREVAIL (ALXN1720-MG-301) is a global, Phase III, randomised, double-blind, placebo-controlled, parallel, multicentre study evaluating the safety and efficacy of Klygefa (gefurulimab) in adults with generalised myasthenia gravis (gMG). The trial enrolled 260 patients from 20 countries across North America, Europe, Asia and the Pacific region. Participants were required to have a confirmed myasthenia gravis diagnosis at least three months prior to the screening visit with a positive serological test for autoantibodies against AChR and Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.9
 
Patients were randomised 1:1 to receive Klygefa or placebo for a total of 26 weeks in the randomised controlled treatment period. Patients received a single weight-based loading dose on Day 1, followed by regular weight-based maintenance dosing beginning on Day 8 and once every week thereafter. The primary endpoint of the change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, a patient-reported scale that assesses patients’ abilities to perform daily activities, was assessed at week 26 along with multiple secondary endpoints evaluating improvement in disease-related measures.9
 
Patients who completed the randomised controlled treatment period were eligible to continue into an open-label extension period evaluating the safety and efficacy of Klygefa, which is ongoing.9
 
Klygefa (gefurulimab)
Klygefa (gefurulimab), a complement C5 inhibitor, is a novel dual-binding nanobody optimised for subcutaneous self-administration for the treatment of AChR-Ab+ gMG. The medication works by binding to the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Klygefa’s concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing. 
 
Klygefa is approved in the European Union (EU), Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.
 
Alexion
Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
References
1.
Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and safety of gefurulimab in generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial. JAMA Neurol. 2026 Jul 27.
2.
Jung-Plath W, et al. Assessment of myasthenia gravis patients’ quality of life. The Journal of Neurosurgical Nursing. 2023;12(2):74-83.
3.
AstraZeneca Data on File - Epidemiology estimates are composed of a triangulation of different data sources including Data Monitor, Decision Resources Group, Kantar Health, and internal input. Available here. Accessed November 2026.
4.
Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.
5.
Huang YF, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve. 2024.
6.
Cavanagh N, et al. Exploring the impairments and allied health professional utilization in people with myasthenia gravis: a cross-sectional study. J Clin Neurosci. 2023;114:9-16.
7.
Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus. 2019.
8.
Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology. 2020;3(2):48-54.
9.
ClinicalTrials.gov. Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis. NCT Identifier: NCT05556096. Available here. Accessed November 2026.
 
Matthew Bowden
Company Secretary
AstraZeneca PLC

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 16 November 2026
 
 
By: /s/ Matthew Bowden
 
Name: Matthew Bowden
 
Title: Company Secretary

Keep reading